Lutetium-177-PSMA in metastasized prostate carcinoma

Lutetium-177 coupled with a ligand for Prostate Specific Membrane Antigen ([177Lu]Lu-PSMA) is a new treatment in The Netherlands. Patients with metastasized castration resistant prostate carcinoma and progressive disease after hormonal therapy and chemotherapy, and no other regular therapeutic optio...

Full description

Saved in:
Bibliographic Details
Published inNederlands tijdschrift voor geneeskunde Vol. 167
Main Authors van Golen, Larissa W, Vogel, Wouter, Lam, Marnix G E H
Format Journal Article
LanguageDutch
Published Netherlands 16.03.2023
Subjects
Dipeptides - adverse effects
Humans
Male
Positron Emission Tomography Computed Tomography
Prostate - pathology
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Radiopharmaceuticals - adverse effects
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:Lutetium-177 coupled with a ligand for Prostate Specific Membrane Antigen ([177Lu]Lu-PSMA) is a new treatment in The Netherlands. Patients with metastasized castration resistant prostate carcinoma and progressive disease after hormonal therapy and chemotherapy, and no other regular therapeutic options, can be referred. A good clinical performance state, adequate bone marrow function and a PSMA PET/CT showing adequate targeting in all metastases are essential. The therapy consists of four to six intravenous administrations of 7.4 GBq [177Lu]Lu-PSMA, six weeks apart. Side effects are mild and consist of xerostomia, fatigue and bone marrow depression. This therapy is currently administered only in a few hospitals in The Netherlands, mainly in research setting. An EMA registered product is expected at the end of 2022, which can contribute to better availability for reimbursed treatment.
ISSN:0028-2162
1876-8784